SCHEMBL10163672

SCHEMBL10163672

COc1cc2cccc(C)c2cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
CYP1A2 P05177 4/20 0.50
HPGD P15428 4/20 0.50
HSD17B10 Q99714 4/20 0.50
CYP2A6 P11509 3/20 0.50
NQO1 P15559 1/20 0.47
KDM4E B2RXH2 5/20 0.46
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
RAC1 P63000 2/20 0.44
MAPT P10636 3/20 0.44
CYP3A4 P08684 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.41
SOS1 Q07889 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8530814 0.85 CYP1A2 (0.44) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL19110425 0.82 ALDH1A1 (0.43) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL2971769 0.82 POLB (0.47) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL598230 0.79 CYP1A2 (0.65) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL19612294 0.79 CYP1A2 (0.46) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL17912847 0.79 CYP1A2 (0.46) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL8501456 0.78 KDM4E (0.52) ALDH1A1CYP1A2HPGDHSD17B10NQO1
SCHEMBL426014 0.78 ALDH1A1 (0.48) ALDH1A1HPGDHSD17B10NQO1KDM4E
SCHEMBL19110427 0.77 CYP1A2 (0.41) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6
SCHEMBL11629826 0.77 CYP1A2 (0.75) ALDH1A1CYP1A2HPGDHSD17B10CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170336728-A1 ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF CANON KABUSHIKI KAISHA (JP) 2017-11-23 US disclosed
EP-3242897-A1 ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF C/o Canon Kabushiki Kaisha (JP) 2017-11-15 EP disclosed
CN-107108774-A Ultra-violet solidified fluid composition, the uv-curing type ink jet ink using it, ultraviolet hardening wet type electrophotographic liquid developer, ultraviolet hardening electrostatic inkjet ink and image forming method 佳能株式会社 2017-08-29 CN disclosed
WO-2016111380-A1 ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF CANON KABUSHIKI KAISHA (JP) 2016-07-14 WO disclosed
US-20120022061-A1 BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS RUGTERS, THE STATE UNIVERSITY OF NEW JERSEY 2012-01-26 US disclosed
WO-2010083436-A1 BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022061-A1 BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS CCNT1, XPO4, XDH ALDH1A1 3095/4885CYP1A2 127/4885HPGD 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.